Hormonal
Preserving or recovering endogenous beta cell function through reduction of beta cell workload (via lifestyle modification, metformin, or TZDs) is the primary therapeutic strategy for managing Type 2 Diabetes, as opposed to exogenous insulin supplementation which causes adverse effects.
Focus on treatments that support your body's natural insulin production rather than just replacing it. This means prioritizing lifestyle changes (weight loss, exercise) and medications like Metformin or TZDs that reduce the workload on your pancreas. Avoiding excessive exogenous insulin helps prevent weight gain and hypoglycemia, which are linked to worse long-term outcomes.
Therefore, to overcome these issues of current therapy of T2DM, it is inevitably important to preserve or recover endogenous beta cell function and physiological insulin secretion in patients with T2DM. To date, the most effective therapeutic strategy to preserve or recover beta cell function is likely to be to reduce beta cell workload or induce beta cell rest.
Why this rating
Based on a review of multiple RCTs (UKPDS, ADOPT, TODAY, ORIGIN) and cohort studies.
Source
Importance of Beta Cell Function for the Treatment of Type 2 Diabetes
Yoshifumi Saisho · Journal of Clinical Medicine · 2014
DOI 10.3390/jcm3030923
More from this paper
- Lower baseline beta cell function (measured by postprandial C-peptide index) is strongly associated with poorer glycemic control, higher HbA1c, and greater glycemic variability, regardless of whether the patient is treated with oral agents or insulin.Good
- Postprandial hyperglycemia and glycemic variability are more strongly correlated with cardiovascular disease and mortality than fasting hyperglycemia alone, and controlling postprandial excursions reduces oxidative stress and hypoglycemia risk.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →